• / Free eNewsletters & Magazine
  • / My Account
Home>Gilead Sciences Soars on “Striking” Clinical Trial Data

Gilead Sciences Soars on “Striking” Clinical Trial Data

Perspectives Content Submission

Fri, 3 Feb 2012

On Thursday after the closing bell, Gilead Sciences (NASDAQ:  GILD ) released its Q4 earnings results. While the biotech giant missed analysts earnings estimates, sales numbers for the quarter came in slightly higher than projected. More importantly, Gilead management announced positive clinical da
Upcoming Events

©2014 Morningstar Advisor. All right reserved.